Research and Pipeline

ACM Biolabs operations build on its core technology, which is a unique blend of the latest advances in polymer chemistry and cell-free protein expression. Our synthetic biology approach allows us to generate high quality membrane protein drug targets and with extremely short turn-around times. We have developed a pipeline of antibodies and vaccines.

Our current research programs include discovery and development of antibodies against a current human epidemic, and development and production of vaccines against animal diseases.

In addition to developing our own pipeline we also provide customers with stable protein preparations, including detailed functional and structural characterization information, in order to lower the entry barrier for our clients’ discovery programs. This enables them to reduce development times and costs and to address targets that they are unable to with other technologies.